Global Information
회사소개 | 문의 | 비교리스트

알코올사용장애(AUD) : 시장 인사이트, 역학, 시장 예측(2032년)

Alcohol Use Disorder (AUD) - Market Insight, Epidemiology And Market Forecast - 2032

리서치사 DelveInsight Business Research LLP
발행일 2022년 09월 상품코드 1126001
페이지 정보 영문 152 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 7,500 ₩ 10,851,000 PDF (Single User License)
US $ 15,000 ₩ 21,703,000 PDF (Site License)
US $ 22,500 ₩ 32,555,000 PDF (Global License)


알코올사용장애(AUD) : 시장 인사이트, 역학, 시장 예측(2032년) Alcohol Use Disorder (AUD) - Market Insight, Epidemiology And Market Forecast - 2032
발행일 : 2022년 09월 페이지 정보 : 영문 152 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 7개국의 알코올사용장애(AUD) 시장 규모는 2021년에 5억 6,400만 달러에 달하고, 조사기간 중(2019-2032년)에 8.8%의 CAGR로 증가할 것으로 예측됩니다. AUD 진단된 유병자수 증가에 힘입어 시장 규모는 향후 몇 년간 확대 경향이 지속될 것으로 예측됩니다.

국가별 시장 규모는 미국이 가장 크고, 유럽 5개국(독일, 이탈리아, 프랑스, 스페인, 영국) 및 일본이 뒤를 잇는 규모를 보유하고 있습니다. 유럽 5개국 중에서는 독일이 가장 시장 규모가 크고, 2021년에는 약 3,570만 달러를 기록했습니다. 또한 일본의 시장 규모는 2021년에 약 1,020만 달러를 기록했습니다.

세계 주요 7개국 - 미국, 유럽 주요 5개국(EU5 : 프랑스·독일·이탈리아·스페인·영국), 일본 - 의 알코올사용장애 역학적 동향과 향후 시장 전망에 대해 분석했으며, 질환 개요와 시장의 기본 구조, 현재 치료법과 미충족 수요, 유병자수 동향 전망, 출시된/임상시험중인 치료제 프로파일, 세계 전체/각국의 시장 규모(2019-2032년), 주요 시장 성장 촉진·억제요인 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 분석 개요

제3장 AUD : 시장 개요

  • 시장 점유율 : 치료법별(2019년)
  • 시장 점유율 : 치료법별(2032년)

제4장 AUD 시장 : 향후 전망

제5장 AUD : 주요 요약

제6장 주요 사건

제7장 질환 배경과 개요

  • 알코올사용장애(AUD) : 개요
  • 정의
  • 원인과 위험인자
  • 알코올 중독 아류형
  • 병태생리학
    • 알코올 중독 병태의 신경면역 활성화
  • AUD 유전학
  • 진단
  • 바이오마커
  • 치료와 관리
    • 치료 가이드라인

제8장 역학과 환자수

  • 주요 조사 결과
  • 역학적 분석 방법
  • 가정과 이론적 근거 : 주요 7개국
    • AUD 진단된 유병자수 : 12개월간
    • AUD 진단된 유병자수 : 성별
    • AUD 진단된 유병자수 : 종류별
    • AUD 치료 건수
  • 주요 7개국의 AUD 총유병자수 : 과거 12개월
  • 미국
    • AUD 진단된 유병자수 : 12개월간
    • AUD 진단된 유병자수 : 성별
    • AUD 진단된 유병자수 : 종류별
  • 유럽 5개국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제9장 환자 여정

제10장 시판약

  • 주요 경쟁사
  • VIVITROL(naltrexone) : Alkermes
    • 제품 설명
    • 규제 마일스톤
    • 기타 개발 활동
    • 임상시험 정보
    • 안전성과 유효성
    • 제품 프로파일
  • SELINCRO(nalmefene) : Lundbeck/Otsuka Pharmaceuticals

제11장 신약

  • 키 크로스 경쟁
  • AD04(ondansetron) : Adial Pharmaceuticals
    • 제품 개요
    • 기타 개발 활동
    • 임상 개발
    • 임상시험 정보
    • 안전성과 유효성
    • 제품 프로파일
    • 애널리스트의 견해
  • MN-166(ibudilast) : MediciNova
  • CORT 118335(Miricorilant)(mifepristone) : Corcept Therapeutics
  • ASP 8062 : Astellas Pharma
  • BP1.3656 : Bioprojet

제12장 알코올사용장애(AUD) : 시장 분석

  • 주요 조사 결과
  • AUD 시장 조사 방법
  • 주요 시장 예측 가정
  • 시장 전망
  • 속성 분석
  • 주요 7개국의 AUD 시장 규모
  • 주요 7개국의 AUD 시장 규모 : 치료제별
  • 미국의 AUD 시장 규모
    • 전체 시장 규모
    • 시장 규모 : 치료제별
  • 유럽 5개국의 AUD 시장 규모
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본의 AUD 시장 규모

제13장 KOL의 견해

  • 미국
  • 유럽 5개국
  • 일본

제14장 시장 성장 촉진요인

제15장 시장 성장 억제요인

제16장 SWOT 분석

제17장 미충족 수요

제18장 시장 접근과 상환

제19장 부록

제20장 DelveInsight 서비스 내용

제21장 면책사항

제22장 DelveInsight 소개

KSM 22.09.23

List of Tables

  • Table 1: Summary of AUD Market and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM, in Thousands (2019-2032)
  • Table 4: 12-month Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
  • Table 5: Gender-specific Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
  • Table 6: Type-specific Diagnosed Prevalent Cases of AUD in the US, in Thousands (2019-2032)
  • Table 7: 12-month Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
  • Table 8: Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
  • Table 9: Type-specific Diagnosed Prevalent Cases of AUD in the EU-5, in Thousands (2019-2032)
  • Table 10: 12-month diagnosed prevalent cases of AUD in Germany, in Thousands (2019-2032)
  • Table 11: Gender-specific Diagnosed Prevalent Cases of AUD in Germany, in Thousands (2019-2032)
  • Table 12: Type-specific Diagnosed Prevalent Cases of AUD in Germany, in Thousands (2019-2032)
  • Table 13: 12-month diagnosed prevalent cases of AUD in France, in Thousands (2019-2032)
  • Table 14: Gender-specific Diagnosed Prevalent Cases of AUD in France, in Thousands (2019-2032)
  • Table 15: Type-specific Diagnosed Prevalent Cases of AUD in France, in Thousands (2019-2032)
  • Table 16: 12-month diagnosed prevalent cases of AUD in Italy, in Thousands (2019-2032)
  • Table 17: Gender-specific Diagnosed Prevalent Cases of AUD in Italy, in Thousands (2019-2032)
  • Table 18: Type-specific Diagnosed Prevalent Cases of AUD in Italy, in Thousands (2019-2032)
  • Table 19: 12-month diagnosed prevalent cases of AUD in Spain, in Thousands (2019-2032)
  • Table 20: Gender-specific Diagnosed Prevalent Cases of AUD in Spain, in Thousands (2019-2032)
  • Table 21: Type-specific Diagnosed Prevalent Cases of AUD in Spain, in Thousands (2019-2032)
  • Table 22: 12-month diagnosed prevalent cases of AUD in the UK, in Thousands (2019-2032)
  • Table 23: Gender-specific Diagnosed Prevalent Cases of AUD in the UK, in Thousands (2019-2032)
  • Table 24: Type-specific Diagnosed Prevalent Cases of AUD in the UK, in Thousands (2019-2032)
  • Table 25: 12-month Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)
  • Table 26: Gender-specific Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)
  • Table 27: Type-specific Diagnosed Prevalent Cases of AUD in Japan, in Thousands (2019-2032)
  • Table 28: Comparison of Marketed Drugs
  • Table 29: VIVITROL (naltrexone) Clinical Trial Description, 2022
  • Table 30: SELINCRO (nalmefene) Clinical Trial Description, 2022
  • Table 31: Comparison of emerging drugs under development
  • Table 32: AD04 (ondansetron), Clinical Trial Description, 2022
  • Table 33: MN-166 (ibudilast), Clinical Trial Description, 2022
  • Table 34: CORT 118335 (Miricorilant/mifepristone), Clinical Trial Description, 2022
  • Table 35: ASP 8062, Clinical Trial Description, 2022
  • Table 36: BP1.3656, Clinical Trial Description, 2022
  • Table 37: Key Market Forecast Assumptions for AD04 (ondansetron)
  • Table 38: Key Market Forecast Assumptions for CORT118335 (mifepristone)
  • Table 39: Key Market Forecast Assumptions for MN-166 (ibudilast)
  • Table 40: Market Size of AUD in the 7MM in USD Million (2019-2032)
  • Table 41: Market Size of AUD by Therapies in the 7MM, in USD Million (2019-2032)
  • Table 42: Market Size of AUD in the US, in USD Million (2019-2032)
  • Table 43: Market Size of AUD by Therapies in the US, in USD Million (2019-2032)
  • Table 44: Market Size of AUD in the EU-5, in USD Million (2019-2032)
  • Table 45: Market Size of AUD in Germany, in USD Million (2019-2032)
  • Table 46: Market Size of AUD by Therapies in Germany, in USD Million (2019-2032)
  • Table 47: Market Size of AUD in France, in USD Million (2019-2032)
  • Table 48: Market Size of AUD by Therapies in France, in USD Million (2019-2032)
  • Table 49: Market Size of AUD in Italy, in USD Million (2019-2032)
  • Table 50: Market Size of AUD by Therapies in Italy, in USD Million (2019-2032)
  • Table 51: Market Size of AUD in Spain, USD Million (2019-2032)
  • Table 52: Market Size of AUD by Therapies in Spain, in USD Million (2019-2032)
  • Table 53: Market Size of AUD in the UK, USD Million (2019-2032)
  • Table 54: Market Size of AUD by Therapies in the UK, in USD Million (2019-2032)
  • Table 55: Market Size of AUD by Therapies in the EU-5, in USD Million (2019-2032)
  • Table 56: Market Size of AUD in Japan, in USD Million (2019-2032)
  • Table 57: Market Size of AUD by Therapies in Japan, in USD Million (2019-2032)

List of Figures

  • Figure 1: Causes and risk factors
  • Figure 2: Natural history of alcohol use disorders
  • Figure 3: Neuroimmune contributions to the cycle of addiction
  • Figure 4: Neuron-glia cell-cell interactions in neuroimmune responses to alcohol
  • Figure 5: AUDIT-C questionnaire
  • Figure 6: Summary of available psychological treatments for AUD
  • Figure 7: Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM (2019-2032)
  • Figure 8: 12-month Diagnosed Prevalent Cases of AUD in the US (2019-2032)
  • Figure 9: Gender-specific Diagnosed Prevalent Cases of AUD in the US (2019-2032)
  • Figure 10: Type-specific Diagnosed Prevalent Cases of AUD in the US (2019-2032)
  • Figure 11: 12-month Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
  • Figure 12: Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
  • Figure 13: Type-specific Diagnosed Prevalent Cases of AUD in the EU-5 (2019-2032)
  • Figure 14: 12-month diagnosed prevalent cases of AUD in Germany (2019-2032)
  • Figure 15: Gender-specific Diagnosed Prevalent Cases of AUD in Germany (2019-2032)
  • Figure 16: Type-specific Diagnosed Prevalent Cases of AUD in Germany (2019-2032)
  • Figure 17: 12-month diagnosed prevalent cases of AUD in France (2019-2032)
  • Figure 18: Gender-specific Diagnosed Prevalent Cases of AUD in France (2019-2032)
  • Figure 19: Type-specific Diagnosed Prevalent Cases of AUD in France (2019-2032)
  • Figure 20: 12-month diagnosed prevalent cases of AUD in Italy (2019-2032)
  • Figure 21: Gender-specific Diagnosed Prevalent Cases of AUD in Italy (2019-2032)
  • Figure 22: Type-specific Diagnosed Prevalent Cases of AUD in Italy (2019-2032)
  • Figure 23: 12-month diagnosed prevalent cases of AUD in Spain (2019-2032)
  • Figure 24: Gender-specific Diagnosed Prevalent Cases of AUD in Spain (2019-2032)
  • Figure 25: Type-specific Diagnosed Prevalent Cases of AUD in Spain (2019-2032)
  • Figure 26: 12-month diagnosed prevalent cases of AUD in the UK (2019-2032)
  • Figure 27: Gender-specific Diagnosed Prevalent Cases of AUD in the UK (2019-2032)
  • Figure 28: Type-specific Diagnosed Prevalent Cases of AUD in the UK (2019-2032)
  • Figure 29: 12-month Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
  • Figure 30: Gender-specific Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
  • Figure 31: Type-specific Diagnosed Prevalent Cases of AUD in Japan (2019-2032)
  • Figure 32: Patient Journey
  • Figure 33: Market Size of AUD in the 7MM, in USD Million (2019-2032)
  • Figure 34: Market Size of AUD by Therapies in the 7MM, in USD Million (2019-2032)
  • Figure 35: Market Size of AUD in the US, in USD Million (2019-2032)
  • Figure 36: Market Size of AUD by Therapies in the US, in USD Million (2019-2032)
  • Figure 37: Market Size of AUD in the EU-5, USD Million (2019-2032)
  • Figure 38: Market Size of AUD by Therapies in the EU-5, in USD Million (2019-2032)
  • Figure 39: Market Size of AUD in Germany, in USD Million (2019-2032)
  • Figure 40: Market Size of AUD by Therapies in Germany, in USD Million (2019-2032)
  • Figure 41: Market Size of AUD in France, in USD Million (2019-2032)
  • Figure 42: Market Size of AUD by Therapies in France, in USD Million (2019-2032)
  • Figure 43: Market Size of AUD in Italy, in USD Million (2019-2032)
  • Figure 44: Market Size of AUD by Therapies in Italy, in USD Million (2019-2032)
  • Figure 45: Market Size of AUD in Spain, USD Million (2019-2032)
  • Figure 46: Market Size of AUD by Therapies in Spain, in USD Million (2019-2032)
  • Figure 47: Market Size of AUD in the UK, USD Million (2019-2032)
  • Figure 48: Market Size of AUD by Therapies in the UK, in USD Million (2019-2032)
  • Figure 49: Market Size of AUD in Japan, USD Million (2019-2032)
  • Figure 50: Market Size of AUD by Therapies in Japan, in USD Million (2019-2032)
  • Figure 51: Market Drivers
  • Figure 52: Market Barriers
  • Figure 53: SWOT Analysis
  • Figure 54: Unmet Needs

DelveInsight's 'Alcohol Use Disorder - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Alcohol Use Disorder, historical and forecasted epidemiology as well as the Alcohol Use Disorder market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Alcohol Use Disorder market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM Alcohol Use Disorder market size from 2019 to 2032. The Report also covers current Alcohol Use Disorder treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032.

Alcohol Use Disorder Understanding and Treatment Algorithm

Alcohol Use Disorder Overview

Alcohol use disorder (AUD) is a highly prevalent, chronic, relapsing condition characterized by an impaired ability to stop or control alcohol use despite significant impairment, distress, or other adverse consequences. It is one of the most common substance use disorders globally with millions impacted by it. Its variability in clinical presentation, suggests a complex interaction between various environmental, physiological, psychological, social, and biological factors resulting in disease development and progression.

It is a highly heterogeneous condition with complex biology, that impacts a person physically, emotionally, and socially and is controlled by many genes and gene-by-environment interactions, wherein a robust genetic influence predisposes certain individuals to develop AUD. A serious public health threat, it causes significant societal harm with high morbidity and mortality.

A person with AUD may experience both intoxication and withdrawal symptoms such as unstable moods, poor judgment, slurred speech, problems with attention or memory, poor coordination, sweating, rapid heartbeat, hand tremors, problems sleeping, nausea and vomiting, hallucinations, restlessness and agitation, anxiety, and occasionally seizures. It is classified as mild, moderate, or severe, based on the number of symptoms experienced by an individual.

Alcohol Use Disorder Diagnosis

The US Preventive Services Task Force has recommended three methods to screen for heavy alcohol use. These methods are the Alcohol Use Disorders Identification Test (AUDIT), the AUDIT-C, or a single question such as "How many times in the past year have you had 5 (for men) or 4 (for women) or more drinks in a day?"

The diagnosis of AUD requires testing an individual based on DSM-V diagnostic criteria, to access if symptoms of AUD are present. DSM-V lists various potential criteria for AUD, covering four main aspects of alcohol use which are impaired control, social impairment, risky use, and pharmacological effects. The presence of at least two of these symptoms indicates an AUD. DSM-V criteria also help determine the severity of AUD. Based on the number of symptoms present the individual is classified into mild, moderate, and severe cases of AUD.

Besides the DSM criteria, another internationally accepted diagnostic criteria is the ICD published by the World Health Organization (WHO). Alcohol Dependence Syndrome according to ICD-10 has 6 central features, of which the presence of 3 or more in a clustered way, typically over 12 months or more is indicative of AUD.

Continued in the report…..

Alcohol Use Disorder Treatment

Management strategies for patients presenting with AUD need to be tailored depending on the presenting complaint, the level and duration of use, the severity of dependence, the presence of any additional comorbid substance use disorders, any physical and/or mental health conditions; and motivation to change. Management always needs to start with the engagement of the patient in the process and understanding their initial goals for treatment.

Mostly the main goal of AUD treatment is either complete abstinence or reduction of heavy drinking and the current treatment options include medication-assisted treatment, behavioral interventions, detox, and psychosocial assistance from rehab and support groups. The mainstay treatment though is psychosocial intervention but with high relapse rates, the best way is to combine pharmacotherapy with psychosocial counseling and intervention.

Currently, there are four US FDA-approved medication-assisted treatments for AUD, that includes Acamprosate, ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone). Besides these TOPAMAX (topiramate) is also endorsed by the National Institute on Alcohol Abuse and Alcoholism for the treatment of AUD.

Moreover, SELINCRO (nalmefene) is approved in the EU and Japan and is one of the first drugs that reduces alcohol cravings in individuals on an as-need basis and does not require abstinence. Other drugs are approved in certain specific countries like BACLOCUR (baclofen) in France and Sodium oxybate (SMO) in Italy. The market for AUD is also inclusive of many off-label and generic products such as gabapentin, varenicline, benzodiazepines, memantine, ondansetron, aripiprazole, and suvorexant, among others.

Continued in the report…..

Alcohol Use Disorder Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by 12-month Diagnosed Prevalent Cases of Alcohol Use Disorder, Gender-specific Diagnosed Prevalent Cases of Alcohol Use Disorder, and Type-specific Diagnosed Prevalent Cases of Alcohol Use Disorder scenario of Alcohol Use Disorder in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

  • In 2021, the 12-month diagnosed prevalent cases of AUD were estimated to be 25,027,206 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019-2032).
  • Among the 7MM, the United States accounted for nearly 58% of the total 12-month diagnosed prevalent cases of AUD in the 7MM in the year 2021 which are expected to increase further by 2032.
  • Among the EU5 countries, Germany had the highest 12-month diagnosed prevalent cases of AUD with 2,541,460 cases in 2021, while Spain had the lowest 12-month diagnosed prevalent population of AUD with 1,326,329 cases in 2021.
  • In 2021, the 12-month diagnosed prevalent population of AUD in Japan was found to be 1,161,931, which is expected to change for the study period of 2019-2032.
  • According to estimates based on DelveInsight's epidemiology model for AUD, the gender distribution of the disease suggests a male predominance across the 7MM, with 9,200,239 male and 5,407,953 female cases in the US in 2021.
  • According to estimates based on DelveInsight's epidemiology model for AUD, the type-specific distribution of the disease suggests that young adults make up the majority of the AUD cases (32%), followed by young antisocial cases (21%). While there were least cases of the chronic severe type.

Alcohol Use Disorder Epidemiology

The epidemiology segment also provides the Alcohol Use Disorder epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Alcohol Use Disorder Drug Chapters

The drug chapter segment of the Alcohol Use Disorder report encloses the detailed analysis of Alcohol Use Disorder marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Alcohol Use Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Alcohol Use Disorder Emerging Drugs

AD04 (ondansetron): Adial Pharmaceuticals

AD04 (ondansetron) being developed by Adial Pharmaceuticals is a genetically targeted, serotonin-3 (5HT3) receptor antagonist that interrupts the reinforcing effects of alcohol, and thus reduces the urge to drink. It is being developed for the treatment of AUD in patients of select genotypes. The blockade of 5HT3 receptors influences the dopamine reward system activated by alcohol, decreasing dopamine release and attenuating the craving for alcohol. AD04 contains an ultra-low dose of ondansetron, which is currently marketed as an anti-emetic for post-operative and post-chemotherapy nausea. Adial Pharmaceuticals has completed ONWARD Phase III clinical trials which evaluated the efficacy, safety, and tolerability of AD04 in patients with AUD and selected polymorphisms in the serotonin genes. It plans to submit these results to both the US and European regulatory agencies for further development and is also exploring potential partnership opportunities in both the US and Europe. Also, EMA has accepted Adial's Pediatric Investigation Plan for the development of AD04, for the treatment of AUD in the pediatric population.

Products detail in the report…

MN-166 (ibudilast): MediciNova

MN-166 (ibudilast) being developed by MediciNova is a novel, first-in-class, non-opioid glial cell modulator that inhibits phosphodiesterases (PDE) -4 and PDE-10 and macrophage migration inhibitory factor (MIF). It leads to a decrease in pro-inflammatory cytokines. Ibudilast is being developed to treat AUD through its anti-inflammatory and pro-neurotrophic mechanisms. It suppresses pro-inflammatory cytokines IL-1B, TNF-a, and IL-6 and upregulates the anti-inflammatory cytokine IL-10. MediciNova is currently conducting Phase II trials to evaluate MN-166 for the treatment of AUD. It has an exclusive license agreement with Kyorin Pharmaceutical for the global development and commercialization of MN-166.

Products detail in the report…

CORT118335 (mifepristone): Corcept Therapeutics

CORT118335 by Corcept Therapeutics is a glucocorticoid receptor (GR) antagonist being developed for the treatment of AUD. Aberrant glucocorticoid signaling via GRs plays a critical role in AUD. The GR antagonist mifepristone decreased alcohol consumption in dependence during acute withdrawal and protracted abstinence. However, the regulation of CeA synaptic GABA transmission by GR is currently unknown. Corcept Therapeutics by doing academic collaborations is trying to augment development efforts for the treatment of AUD. Recently a Phase II trial by Scripps Research Institute in collaboration with NIAAA was completed for the treatment of moderate or severe AUD with CORT118335. However further update from the company is awaited.

Products detail in the report…

List of products to be continued in the report…

Alcohol Use Disorder Market Outlook

AUD also has economic consequences, costing a substantial amount annually. Current pharmaceutical and behavioral treatments may assist patients in reducing alcohol use or facilitating alcohol abstinence.

At present, there are four approved therapies for the treatment of AUD that includes disulfiram, Naltrexone (oral), acamprosate, and VIVITROL. Most of these therapies were approved decades ago and have their generics in the market. The current AUD market in the US is dominated by these therapies.

Naltrexone, the best-studied of the approved medications, is an antagonist of the mu-opioid receptor with an additional affinity for kappa and delta opioid receptors. In 1994, the US FDA approved oral naltrexone sold by DuPont under the brand name REVIA for the treatment of alcoholism. Though it significantly reduced alcohol craving and drinking rates it required strict compliance. To address this issue the extended-release depot formulation of naltrexone was developed to improve adherence. In April 2006, the US FDA approved VIVITROL (naltrexone for extended-release injectable suspension) marketed by Alkermes. This once-a-month injectable formulation of naltrexone helped in maintaining therapeutic medication levels in the body through a single intramuscular injection every four weeks. The demand for complete abstinence before the treatment is started is the major disadvantage of Naltrexone. Though an FDA-recommended first-line treatment that reduces binge drinking, naltrexone is a costly drug with an FDA label warning that significantly impacts its market availability.

Another decade-old approved drug, Acamprosate, the first approved treatment for alcohol dependence in Europe, is often considered an 'artificial alcohol' or a 'functional glutamate antagonist. Multiple meta-analyses have found acamprosate to reduce alcohol consumption compared to placebo and increased cumulative duration of abstinence. It is FDA-approved for abstinence maintenance in AUD patients who are abstinent when beginning treatment. Usually administered as the first line of treatment it is best for maintaining sobriety once the patient has achieved abstinence.

ANTABUSE (disulfiram), the first US FDA-approved (in 1951) medication for AUD treatment, is the oldest drug in the AUD market. Marketed by Odyssey pharmaceuticals it is an oral aldehyde dehydrogenase inhibitor that acts by blocking the metabolism of alcohol. NICE guidelines suggest that disulfiram should be used as a second-line treatment when other approved medications fail. However, there is no consensus on the trial methodology for assessing the efficacy of disulfiram since it cannot be appraised fairly in double-blind, RCTs due to its mechanism of action.

Besides these SELINCRO (nalmefene) developed by Lundbeck is approved in the EU and Japan and addresses the need for abstinence in AUD patients. Being the drug that addresses the major unmet of abstinence, it has shown immense success in the European and Japanese markets. However, it has not been approved for sale in the US.

The considerable heterogeneity of AUD patients makes it especially challenging to design a single drug capable of treating AUD patients as a whole. Current pharmacotherapies are often characterized by limited efficacy and there is a large treatment gap in alcohol dependence with the current treatments only moderately effective in preventing relapse. The need for abstinence and the associated social stigma further complicates the treatment regime. The expected launch of potential therapies that include AD04 (ondansetron) (Adial Pharmaceuticals), CORT118335 (mifepristone) (Corcept Therapeutics), and MN-166 (ibudilast) (MediciNova) may address this unmet need, increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of AUD during the forecast period [2022-2032].

According to DelveInsight, the overall dynamics of the AUD market is anticipated to change in the coming years owing to the expected launch of emerging therapies.

Key Findings

  • The market size of the Alcohol Use Disorder in the seven major markets was USD 564.0 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 8.8% for the study period (2019-2032).
  • The launch of potential therapies, AD04 (ondansetron), CORT118335 (mifepristone), and MN-166 (ibudilast) are expected to increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of AUD.
  • The United States accounts for the largest market size for Alcohol Use Disorder, in comparison to the EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
  • Among the EU5 countries, Germany had the highest market size with approximately USD 35.7 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market followed by the UK in 2032.
  • The market size for Alcohol Use Disorder in Japan was valued at approximately USD 10.2 million in 2021. It is expected that the market will increase mainly due to the launch of upcoming therapy during the forecast period (2022-2032).

The United States Market Outlook

This section provides the total Alcohol Use Disorder market size and market size by therapies in the United States.

The EU-5 Market Outlook

The total Alcohol Use Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Alcohol Use Disorder market size and market size by therapies in Japan are provided.

Alcohol Use Disorder Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Alcohol Use Disorder market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Alcohol Use Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alcohol Use Disorder Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Alcohol Use Disorder emerging therapies.

Reimbursement Scenario in Alcohol Use Disorder

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Alcohol Use Disorder market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers a descriptive overview of Alcohol Use Disorder, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Alcohol Use Disorder epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Alcohol Use Disorder is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Alcohol Use Disorder market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Alcohol Use Disorder market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Alcohol Use Disorder market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Alcohol Use Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Alcohol Use Disorder. The launch of emerging therapies will significantly impact the Alcohol Use Disorder market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Alcohol Use Disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Alcohol Use Disorder Pipeline Analysis
  • Alcohol Use Disorder Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alcohol Use Disorder Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Alcohol Use Disorder Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Alcohol Use Disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Alcohol Use Disorder market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Alcohol Use Disorder total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Alcohol Use Disorder market size during the forecast period (2022-2032)?
  • At what CAGR, the Alcohol Use Disorder market is expected to grow at the 7MM level during the forecast period (2022-2032)?
  • What would be the Alcohol Use Disorder market outlook across the 7MM during the forecast period (2022-2032)?
  • What would be the Alcohol Use Disorder market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Alcohol Use Disorder?
  • What is the historical Alcohol Use Disorder patient pool in the United States, the EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Alcohol Use Disorder at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Alcohol Use Disorder?
  • Out of the above-mentioned countries, which country would have the highest incidence population of Alcohol Use Disorder during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Alcohol Use Disorder along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Alcohol Use Disorder in the US and Europe?
  • What are the Alcohol Use Disorder marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Alcohol Use Disorder?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Alcohol Use Disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Alcohol Use Disorder therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alcohol Use Disorder and their status?
  • What are the key designations that have been granted for the emerging therapies for Alcohol Use Disorder?
  • What is the 7MM historical and forecasted market for Alcohol Use Disorder?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving Alcohol Use Disorder.
  • To understand the future market competition in the Alcohol Use Disorder market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Alcohol Use Disorder in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Alcohol Use Disorder market.
  • To understand the future market competition in the Alcohol Use Disorder market.

Table of Contents

1. Key Insights

2. Report Introduction

3. AUD Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of AUD by Therapies in 2019
  • 3.2. Market Share (%) Distribution of AUD by Therapies in 2032

4. AUD Market: Future Perspective

5. Executive Summary of AUD

6. Key Events

7. Disease Background and Overview

  • 7.1. Introduction to AUD
  • 7.2. Definitions
  • 7.3. Causes and risk factors
  • 7.4. Subtypes of Alcoholics
  • 7.5. Pathophysiology
    • 7.5.1. Neuroimmune Activation in the Pathology of Alcoholism
  • 7.6. Genetics of AUD
  • 7.7. Diagnosis
  • 7.8. Biomarkers
  • 7.9. Treatment and Management
    • 7.9.1. Treatment Guidelines
      • 7.9.1.1. American Psychiatric Association Guidelines
      • 7.9.1.2. NICE Guidelines

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Methodology of Epidemiology
  • 8.3. Assumptions and Rationale: the 7MM
    • 8.3.1. 12-month Diagnosed Prevalent Cases of AUD
    • 8.3.2. Gender-specific Diagnosed Prevalent Cases of AUD
    • 8.3.3. Type-specific cases of AUD
    • 8.3.4. Treated Cases of AUD
  • 8.4. Total 12-month Diagnosed Prevalent Cases of AUD in the 7MM
  • 8.5. The US
    • 8.5.1. 12-month Diagnosed Prevalent Cases of AUD in the US
    • 8.5.2. Gender-specific Diagnosed Prevalent Cases of AUD in the US
    • 8.5.3. Type-specific Diagnosed Prevalent Cases of AUD in the US
  • 8.6. The Five European Countries
    • 8.6.1. 12-month Diagnosed Prevalent Cases of AUD in the EU-5
    • 8.6.2. Gender-specific Diagnosed Prevalent Cases of AUD in the EU-5
    • 8.6.3. Type-specific Diagnosed Prevalent Cases of AUD in the EU-5
    • 8.6.4. Germany
      • 8.6.4.1. 12-month diagnosed prevalent cases of AUD in Germany
      • 8.6.4.2. Gender-specific Diagnosed Prevalent Cases of AUD in Germany
      • 8.6.4.3. Type-specific Diagnosed Prevalent Cases of AUD in Germany
    • 8.6.5. France
      • 8.6.5.1. 12-month diagnosed prevalent cases of AUD in France
      • 8.6.5.2. Gender-specific Diagnosed Prevalent Cases of AUD in France
      • 8.6.5.3. Type-specific Diagnosed Prevalent Cases of AUD in France
    • 8.6.6. Italy
      • 8.6.6.1. 12-month diagnosed prevalent cases of AUD in Italy
      • 8.6.6.2. Gender-specific Diagnosed Prevalent Cases of AUD in Italy
      • 8.6.6.3. Type-specific Diagnosed Prevalent Cases of AUD in Italy
    • 8.6.7. Spain
      • 8.6.7.1. 12-month diagnosed prevalent cases of AUD in Spain
      • 8.6.7.2. Gender-specific Diagnosed Prevalent Cases of AUD in Spain
      • 8.6.7.3. Type-specific Diagnosed Prevalent Cases of AUD in Spain
    • 8.6.8. The UK
      • 8.6.8.1. 12-month diagnosed prevalent cases of AUD in the UK
      • 8.6.8.2. Gender-specific Diagnosed Prevalent Cases of AUD in the UK
      • 8.6.8.3. Type-specific Diagnosed Prevalent Cases of AUD in the UK
  • 8.7. Japan
    • 8.7.1. 12-month Diagnosed Prevalent Cases of AUD in Japan
    • 8.7.2. Gender-specific Diagnosed Prevalent Cases of AUD in Japan
    • 8.7.3. Type-specific Diagnosed Prevalent Cases of AUD in Japan

9. Patient Journey

10. Marketed Drugs

  • 10.1. Key Competitors
  • 10.2. VIVITROL (naltrexone): Alkermes
    • 10.2.1. Product Description
    • 10.2.2. Regulatory Milestone
    • 10.2.3. Other Development Activities
    • 10.2.4. Clinical Trial Information
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. SELINCRO (nalmefene): Lundbeck/Otsuka Pharmaceuticals
    • 10.3.1. Product Description
    • 10.3.2. Regulatory Milestone
    • 10.3.3. Other Development Activities
    • 10.3.4. Clinical Trial Information
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile

11. Emerging Drugs

  • 11.1. Key Cross Competition
  • 11.2. AD04 (ondansetron): Adial Pharmaceuticals
    • 11.2.1. Product Description
    • 11.2.2. Other Development Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Clinical Trial Information
    • 11.2.5. Safety and Efficacy
    • 11.2.6. Product Profile
    • 11.2.7. Analysts' Views
  • 11.3. MN-166 (ibudilast): MediciNova
    • 11.3.1. Product Description
    • 11.3.2. Other Development Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Clinical Trial Information
    • 11.3.5. Safety and Efficacy
    • 11.3.6. Product Profile
    • 11.3.7. Analysts' Views
  • 11.4. CORT 118335 (Miricorilant) (mifepristone): Corcept Therapeutics
    • 11.4.1. Product Description
    • 11.4.2. Clinical Development
    • 11.4.3. Clinical Trial Information
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile
    • 11.4.6. Analysts' Views
  • 11.5. ASP 8062: Astellas Pharma
    • 11.5.1. Product Description
    • 11.5.2. Clinical Development
    • 11.5.3. Clinical Trial Information
    • 11.5.4. Safety and Efficacy
    • 11.5.5. Product Profile
    • 11.5.6. Analysts' Views
  • 11.6. BP1.3656: Bioprojet
    • 11.6.1. Product Description
    • 11.6.2. Clinical Development
    • 11.6.3. Clinical Trial Information
    • 11.6.4. Product Profile

12. AUD: Market Analysis

  • 12.1. Key Findings
  • 12.2. Methodology of AUD Market
  • 12.3. Key Market Forecast Assumptions
  • 12.4. Market Outlook
  • 12.5. Attribute Analysis
  • 12.6. Market Size of AUD in the 7MM
  • 12.7. Market Size of AUD by Therapies in the 7MM
  • 12.8. Market Size of AUD in the US
    • 12.8.1. Total Market Size of AUD
    • 12.8.2. Market Size of AUD by Therapies
  • 12.9. Market Size of AUD in the EU-5
    • 12.9.1. Total Market Size of AUD
    • 12.9.2. Market Size of AUD by Therapies
    • 12.9.3. Germany
      • 12.9.3.1. Total Market Size of AUD
      • 12.9.3.2. Market Size of AUD by Therapies
    • 12.9.4. France
      • 12.9.4.1. Total Market Size of AUD
      • 12.9.4.2. Market Size of AUD by Therapies
    • 12.9.5. Italy
      • 12.9.5.1. Total Market Size of AUD
      • 12.9.5.2. Market Size of AUD by Therapies
    • 12.9.6. Spain
      • 12.9.6.1. Total Market Size of AUD
      • 12.9.6.2. Market Size of AUD by Therapies
    • 12.9.7. The UK
      • 12.9.7.1. Total Market Size of AUD
      • 12.9.7.2. Market Size of AUD by Therapies
  • 12.10. Market Size of AUD in Japan
    • 12.10.1. Total Market Size of AUD
    • 12.10.2. Market Size of AUD by Therapies

13. KOL Views

  • 13.1. The United States
  • 13.2. The EU-5
  • 13.3. Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Market Access and Reimbursement

19. Appendix

  • 19.1. Bibliography
  • 19.2. Acronyms and Abbreviations
  • 19.3. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top
전화 문의
F A Q